Uterine sarcoma in the south of Israel: Study of 36 cases

Abstract

Background Uterine sarcomas are rare, characterized by rapid clinical progression and poor prognosis, and their management has been a challenge. The purpose of this study was to investigate the clinical and histologic findings, treatment, and outcome of patients with uterine sarcoma in the south of Israel. Methods Data from the files of 36 patients with uterine sarcoma who were managed at the Soroka Medical Center between January 1961 and December 1994 were evaluated. Results The 5‐year survival rate was 32% overall; 63% for 9 patients with endometrial stromal sarcoma (ESS), 30% for 14 patients with mixed mesodermal sarcoma (MMS) and 18% for 13 patients with leiomyosarcoma (LMS); 41% for 22 patients with Stage I and 19% for 14 patients with Stages II, III, and IV. Only the difference in the 5‐year survival rate between ESS and LMS was statistically significant (P < 0.05). Eleven patients (30.6%) were treated with surgery alone, 4 (11.1%) with surgery followed by pelvic radiotherapy, 11 (30.6%) with surgery followed by chemotherapy, 8 (22.2%) with surgery followed by pelvic radiotherapy and chemotherapy, one (2.8%) with chemotherapy alone, and one (2.8%) had no treatment. Conclusions Uterine sarcomas are aggressive tumors with a poor prognosis. The treatment is surgery generally followed by adjuvant pelvic radiotherapy and/or systemic chemotherapy. J. Surg. Oncol. 64:55–62 © 1997 Wiley‐Liss, Inc.

Response of recurrent uterine high-grade malignant mixed mullerian tumor to letrozole

“…MMMTs or carcinosarcomas account for less than 5% of uterine malignancies but about 37% of all uterine sarcomas (10−13) . Although this tumor is still classified as a type of sarcoma with mixed epithelial and stromal components, increasing evidence indicates that MMMT is of monoclonal origin and may in fact represent metaplastic carcinoma (14) .…”

Primary Ovarian Leiomyosarcoma Is a Very Rare Entity: A Narrative Review of the Literature

“…POLMS was treated by surgical resection in 76/80 (95%) patients [1,2,[4][5][6]9,10,15,16,19,20,22,[25][26][27][28][29][30][31][32][33]. A total of 34/80 (42.5%) patients received surgery without lymphadenectomy [2,9,13,14,16,19,20,22,26,[28][29][30][34][35][36][37]39,40,43,[57][58][59][60]64,65]…”

“…A total of 52/89 (58.4%) patients were stage I, 8/89 (9%) patients were stage II, 25/89 (28%) patients were stage III, and 4/89 (4.6%) patients were stage IV. Mitotic count was reported in 81/113 (71.7%) patients [1,[4][5][6]9,[13][14][15][16][18][19][20]22,23,25,26,28,29,[31][32][33][34][35][36][37][38][39][40][41][43][44][45][46][47]49,[51][52][53][54][55][56][57][58][59][60][61][62][63][64][65], and the mean number of mitoses w...…”

“…Follow-up information was available for 100/113 (88.5%) patients (Table 2) [1,2,4-6,10,13-19, [21][22][23][24][25][26][27][28][29][30][31][32][33]35,36,65,66]. In total, 2/100 (2%) patients died for causes other than POLMS [36,41] and 13/100 (13%) were lost in follow-up [9,20,34,37,43,49,64,67]. A total of 46/100 (46%) patients were alive and disease-free [1,2,4,6,10,15,16,22,[24][25][26][27][28][31][32][33]39,40,42,43,45,…”

“…Follow-up time was available for 99/113 (87.6%) patients [1,2,4-6, 10,14-19,22-24,27,29,30,32,35,36,38,42,45-48,50,53-55,59,61-63,65,66]; mean follow-up was 26 months (range 1-144). In total, 56/99 (56.6%) patients did not relapse [1,2,4,10,13,15,[21][22][23][24][25][26][27][28][29]32,33,36,[39][40][41][42][43]45,47,48,[50][51][52][53][54][55][56][57][58][59]62,65,66], 43/99 (43.4%) of patients relapsed [2,5,6,14,[16][17][18][19]23,…”